EntroGen

Executive Summary

EntroGen is a private molecular diagnostics company specializing in oncology, with a focus on FDA-approved companion diagnostics and research-use-only assays. Its flagship product, the CRCdx® RAS Mutation Detection Kit, is an FDA-approved companion diagnostic for colorectal cancer. The company offers an integrated workflow solution encompassing hardware, reagents, and software for sample preparation to genomic interpretation. Founded in 2008 and headquartered in Woodland Hills, California, EntroGen has established a niche in colorectal cancer diagnostics but faces competition from larger players. Despite limited public information on recent developments, the company's FDA-approved product provides a regulatory advantage and potential for growth through expansion into other cancer types or liquid biopsy applications.

Upcoming Catalysts (preview)

• Q2 2027FDA approval for liquid biopsy version of CRCdx40% success
• Q4 2026New partnership with a major pharma for companion diagnostic development50% success
• Q1 2027Launch of a new assay for lung or pancreatic cancer30% success